Intimacy · Reference
PT-141 + Oxytocin Dosage: Units, mL, mg and Timing for the Combination Vial
This page explains the PT-141 + Oxytocin dosage Pepti prescribes, what the units on the syringe mean, how much of each peptide is in a dose, a chart for this vial, why its numbers differ from PT-141 alone and oxytocin alone, how to use it on the day, how long a vial lasts, what the published studies used, and the side effects to know about. It covers how Pepti prescribes this vial, not protocols from the internet. Nothing here is a reason to change your own dose.
Treatments mentioned
At Pepti, PT-141 + Oxytocin is prescribed as 0.10 mL, which is 10 units on a U-100 insulin syringe, injected under the skin 2 to 4 hours before sexual activity, no more than 8 doses a month. The 5 mL vial holds 10 mg of PT-141 (bremelanotide) and 5 mg of oxytocin, so every 10 unit dose delivers 0.2 mg PT-141 and 0.1 mg oxytocin together, and the vial holds 50 doses. It is used on the occasion, never more than once in 24 hours. Your physician sets your directions after reviewing your intake, and your exact dose and units are printed on the vial.
This page explains the PT-141 + Oxytocin dosage Pepti prescribes, what the units on the syringe mean, how much of each peptide is in a dose, a chart for this vial, why its numbers differ from PT-141 alone and oxytocin alone, how to use it on the day, how long a vial lasts, what the published studies used, and the side effects to know about. It covers how Pepti prescribes this vial, not protocols from the internet. Nothing here is a reason to change your own dose.
PT-141 + Oxytocin Dosage
The short answer
| Product | Vial | Typical directions | Per dose | Doses per vial | Price |
|---|---|---|---|---|---|
| PT-141 + Oxytocin | 5 mL, PT-141 2 mg/mL + oxytocin 1 mg/mL (10 mg PT-141 / 5 mg oxytocin per vial) | Inject 0.10 mL (10 units) subcutaneously 2 to 4 hours prior to sexual activity. No more than 8 doses per month | 0.2 mg PT-141 and 0.1 mg oxytocin | 50 | $259/mo |
The price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. These are the typical printed directions; your own directions are the ones on your vial.
PT-141 + Oxytocin Dosage
What is in the vial
PT-141 + Oxytocin is two separately studied peptides dissolved together in one sterile multi-dose vial by a compounding pharmacy. PT-141 is bremelanotide, a seven-amino-acid cyclic peptide that activates melanocortin receptors in the brain and is described around the desire side of sexual response. Oxytocin is a nine-amino-acid hormone the body already makes, released around orgasm, with established roles in labour and milk let-down. Both are the active ingredients of FDA-approved drugs for other purposes; the combination itself has never been studied as a combination, in people or in animals. The full reference is what is PT-141 + Oxytocin.
| Component | Concentration | Per vial | Per 0.10 mL dose |
|---|---|---|---|
| PT-141 (bremelanotide) | 2 mg/mL | 10 mg | 0.2 mg |
| Oxytocin | 1 mg/mL | 5 mg | 0.1 mg |
| Total | 15 mg | 0.3 mg |
The ratio is fixed, two parts PT-141 to one part oxytocin by mass, so every draw delivers the same split. Prescribers aim PT-141 at desire and oxytocin at the orgasmic phase and closeness afterwards; that is a rationale, not a finding, and no study has tested whether oxytocin adds anything to PT-141.
PT-141 + Oxytocin Dosage
PT-141 + Oxytocin dosage in units, mL and mg
Pepti's directions are written in two forms, millilitres and units, because prescriptions are written in millilitres and insulin syringes are marked in units. On a U-100 insulin syringe, 1 unit is 0.01 mL, so 100 units is 1 mL and 10 units is 0.10 mL. A unit is a volume mark on the barrel, not a measure of how strong the medication is, and it is not the same thing as the "IU" used for oxytocin in hospital products and nasal spray studies. Units on the syringe only mean something alongside the concentrations on the label.
| What you read | Value | Where it comes from |
|---|---|---|
| Dose volume | 0.10 mL | Printed on the vial |
| On a U-100 insulin syringe | 10 units | 0.10 mL x 100 units per mL |
| PT-141 concentration | 2 mg/mL | Printed on the vial |
| PT-141 per dose | 0.2 mg | 2 mg/mL x 0.10 mL |
| Oxytocin concentration | 1 mg/mL | Printed on the vial |
| Oxytocin per dose | 0.1 mg | 1 mg/mL x 0.10 mL |
| Doses per vial | 50 | 5 mL divided by 0.10 mL |
| Monthly ceiling | 8 doses | Printed on the vial |
That arithmetic is a way to read a label, not a way to set a dose. A vial labelled 10 mg PT-141 and 5 mg oxytocin is not one dose: it is fifty small ones. If your label and your syringe seem to disagree, do not dose; message your care team. How long does a peptide vial last explains every number on a vial label.
PT-141 + Oxytocin Dosage
PT-141 + Oxytocin dosage chart: units to mL to mg
The chart below is the conversion for this vial, drawn with a U-100 insulin syringe. It is math only. It is not a menu of doses, and the only line that applies to you is the one that matches the number printed on your vial.
| Syringe mark (U-100) | Volume | PT-141 | Oxytocin |
|---|---|---|---|
| 5 units | 0.05 mL | 0.1 mg | 0.05 mg |
| 10 units (Pepti's typical directions) | 0.10 mL | 0.2 mg | 0.1 mg |
| 15 units | 0.15 mL | 0.3 mg | 0.15 mg |
| 20 units | 0.20 mL | 0.4 mg | 0.2 mg |
| 25 units | 0.25 mL | 0.5 mg | 0.25 mg |
| 50 units | 0.50 mL | 1 mg | 0.5 mg |
| 100 units | 1 mL | 2 mg | 1 mg |
The rule behind every row: units divided by 100 gives millilitres; multiply millilitres by 2 for PT-141 and by 1 for oxytocin. Those multipliers only hold for this vial. A chart written for the PT-141 vial or the oxytocin vial gives different figures for the same units, which is the main reason not to dose from a chart, including this one.
PT-141 + Oxytocin Dosage
How the combination compares with PT-141 alone and oxytocin alone
People often assume the combination is PT-141 with a little oxytocin added at the usual PT-141 dose. It is not. The three products are different concentrations with different printed directions:
| PT-141 + Oxytocin | PT-141 alone | Oxytocin alone | |
|---|---|---|---|
| What is in the vial | 10 mg PT-141, 5 mg oxytocin in 5 mL | 10 mg PT-141 in 5 mL (2 mg/mL); also as a Pen | 10 mg oxytocin in 5 mL (2 mg/mL) |
| Typical directions | 0.10 mL (10 units) 2 to 4 hours before sexual activity, no more than 8 doses a month | 0.50 mL (50 units) 2 to 4 hours before sexual activity, no more than 4 doses a month | 0.18 mL (18 units) once daily |
| Per dose | 0.2 mg PT-141 and 0.1 mg oxytocin | 1 mg PT-141 | 0.36 mg oxytocin |
| Doses per vial | 50 | 10 | 27 whole doses |
| Price | $259/mo | $259/mo | $239/mo |
What the numbers show
A dose from the combination vial carries one fifth of the PT-141 in a dose from the PT-141 vial, which is why its monthly ceiling is set differently. The oxytocin per dose is also smaller than a daily dose from the oxytocin vial, and it is given on the occasion rather than every day. The labels are not interchangeable: 10 units from the combination vial, 50 units from the PT-141 vial and 18 units from the oxytocin vial are three different products with three different directions. Never carry a number from one label to another, and never use two of these products together unless your physician has prescribed exactly that. The PT-141 numbers are covered in PT-141 dosage.
PT-141 + Oxytocin Dosage
How to use PT-141 + Oxytocin
PT-141 + Oxytocin is not a daily medication. Each dose is taken for an occasion, and each one stands on its own. This is the practical sequence, in the order it happens.
1. Check the label first
Read the dose, the timing window and the monthly ceiling on your vial. The label is the instruction; this page is background. Check the beyond-use date as well, because a vial used a few times a month can sit in the fridge for a while between uses.
2. Time it 2 to 4 hours ahead
Pepti's directions say 2 to 4 hours before sexual activity. That window is set by the PT-141 component: the approved bremelanotide label reports peak blood levels about an hour after a subcutaneous dose and a half-life of about 2.7 hours, and the blood pressure effect peaks two to four hours after a dose. The live oxytocin reference describes oxytocin as fast and short, with a plasma half-life of a few minutes. How the oxytocin component behaves on a 2 to 4 hour timing, given alongside PT-141, has not been studied. Your own directions say which window applies to you.
3. Draw and inject under the skin
Use a fresh sterile syringe every time, wipe the vial stopper and the skin with an alcohol prep pad, draw to the 10 mark if that is what your label says, and inject into the fat layer under the skin, not the muscle. The abdomen and thigh are the usual sites, rotated. A 10 unit draw is small, so read the barrel at eye level. Technique is in how to inject peptides safely.
4. One dose, then wait
Never take a second dose within 24 hours. The approved bremelanotide label states that consecutive doses within 24 hours have not been shown to add anything and may add to the effect on blood pressure. If a dose did not seem to work, that is a message to your care team, not a reason for another draw.
5. Expect the first dose to be about side effects
Nausea, when it happens, usually starts within an hour and lasts about two, and it is most common with the first dose. Prescribers suggest taking a first dose on an occasion where a poor response would not matter.
6. Back in the fridge
Return the vial to the refrigerator and do not freeze it. Vials ship refrigerated with ice packs, and the beyond-use date runs from first puncture. How to store peptides covers storage.
Directions say What it means in practice 0.10 mL (10 units) Draw to the 10 mark on a U-100 insulin syringe Subcutaneously Into the fat layer, abdomen or thigh, rotating sites 2 to 4 hours prior to sexual activity Dose ahead of time, not at the moment No more than 8 doses per month A ceiling, not a target Once in 24 hours at most No second dose the same day
PT-141 + Oxytocin Dosage
How long a PT-141 + Oxytocin vial lasts
Because it is used on occasions, a vial is not consumed on a calendar the way a weekday peptide is. The arithmetic:
| Step | Value |
|---|---|
| Dose | 10 units, 0.10 mL |
| Doses per vial | 50 (5 mL divided by 0.10 mL) |
| Used over the full vial | 10 mg PT-141 and 5 mg oxytocin |
| Ceiling | 8 doses a month |
| At the ceiling | 50 doses is more than six months of doses |
| In practice | The beyond-use date printed on the label decides when the vial is replaced |
The dose count will almost always outlast the beyond-use date, so do not read a half-full vial as a reason to use it more often, and do not keep using it past the date on the label. One vial per fill, never a stockpile. If you have a question about when your next vial ships, message your care team.
PT-141 + Oxytocin Dosage
Why the monthly ceiling exists
The ceiling is a safety limit taken from the approved bremelanotide label, which caps use at eight doses a month and once in 24 hours. It comes from two effects of the PT-141 component:
| Effect | What was reported | Why it limits frequency |
|---|---|---|
| Blood pressure | A transient rise of about 6 mmHg systolic and 3 mmHg diastolic at most, peaking two to four hours after a dose, usually back to baseline within twelve, with heart rate falling by up to 5 beats a minute | Each dose adds hours of raised blood pressure |
| Focal hyperpigmentation | 1% of women dosing up to eight times a month; 38% of people dosed daily for eight days in a separate study; face, gums and breasts; not always reversible | Risk rises with more frequent dosing |
A compounded vial does not change that pharmacology, and the smaller PT-141 amount per dose in the combination vial has not been studied for these effects either way.
PT-141 + Oxytocin Dosage
What the studies used, and why that is not your dose
Both components have human research, and the doses in it are often quoted online as if they were protocols. None of it tested this vial:
| Study | Who | How it was dosed |
|---|---|---|
| RECONNECT, two phase 3 trials, Obstetrics & Gynecology, 2019 | 1,267 premenopausal women with acquired, generalised hypoactive sexual desire disorder | PT-141 1.75 mg by single-dose autoinjector, as needed, for 24 weeks |
| Two 2004 studies, International Journal of Impotence Research | Healthy men and men with mild-to-moderate erectile dysfunction | PT-141 subcutaneously above 1 mg, and 4 mg and 6 mg in men who responded inadequately to sildenafil |
| 2014 couples study, Hormones and Behavior | 29 healthy couples | Oxytocin 24 IU by nasal spray before sex at home |
| 2015 crossover trial, Fertility and Sterility | 30 pre- and postmenopausal women with sexual dysfunction | Oxytocin 32 IU by nasal spray before intercourse, eight weeks per arm |
| Any study of the combination | Nobody | Never run |
The honest reading: the PT-141 trials used doses well above the 0.2 mg in a combination dose, and every oxytocin study used a nasal spray measured in IU, which cannot be converted to the milligrams on this vial. The 2014 couples study reported effects on orgasm intensity and contentment after sex, not on desire or arousal; the 2015 trial in women found oxytocin no better than placebo. That is why your directions come from a physician who has reviewed your intake, not from a study table. What the research looked at is in PT-141 benefits and what is oxytocin.
PT-141 + Oxytocin Dosage
What changes the directions
Your physician sets your directions after reviewing your intake. Things that can lead to different directions, or a different product, include:
| What can change | How it shows up |
|---|---|
| Combination or a single component | If desire is the whole question, PT-141 alone has its own label; if closeness is, oxytocin alone has its own |
| Blood pressure or heart history | Uncontrolled hypertension and known cardiovascular disease are reasons it is not prescribed |
| Your other medications | PT-141 can slow gastric emptying and reduce absorption of oral medicines taken around the same time, and it should not be used with oral naltrexone |
| Pregnancy | Not used; oxytocin contracts the uterus |
| How you respond | Marked nausea, new skin darkening or anything unexpected goes to your physician, who may revise your directions |
When directions change, the new numbers are printed on the new label. Never carry a number over from a previous fill. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
PT-141 + Oxytocin Dosage
Side effects, in summary
The combination's side effects are dominated by its PT-141 component. The rates below are from the phase 3 trials of bremelanotide at 1.75 mg; there are no systematic safety data for oxytocin at the small subcutaneous doses in this vial. The full picture is in PT-141 side effects.
| What is reported | How often in the phase 3 trials | What to do |
|---|---|---|
| Nausea | 40% of women vs 1.3% on placebo | Usually eases after the first dose; tell your care team if it is marked |
| Flushing | 20% | Usually short-lived |
| Injection-site reactions | 13% | Rotate sites |
| Headache | 11% | Report it if it persists |
| Vomiting | 5% | Report it |
| New darkening of skin, gums or breasts | 1% at up to eight doses a month | Report it promptly |
| Chest pain, a severe headache, trouble breathing, or an erection lasting more than four hours | Not routine | Call 911 or go to an emergency department, then tell your physician |
If you think you have drawn too much, for example 50 units instead of 10, call Poison Control at 1-800-222-1222 and message your care team. Do not take another dose to compensate for anything.
Who should not take PT-141 + Oxytocin, or should discuss it first: anyone with uncontrolled high blood pressure or heart disease; anyone taking oral naltrexone; anyone with a history of melanoma or atypical moles; anyone pregnant or breastfeeding. Bremelanotide is not named on the 2026 WADA Prohibited List, but tested athletes should check their own sport's current rules.
Both active ingredients are components of FDA-approved drugs, which is how a licensed pharmacy may compound them, but the combination vial is a different formulation prepared to a prescription. It has not been reviewed by the FDA, and compounded medications are not FDA approved.
PT-141 + Oxytocin Dosage
Where to get PT-141 + Oxytocin prescribed
PT-141 + Oxytocin cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested, so even the two concentrations your units chart depends on are unknown. The prescription route:
- Complete a free online intake covering your history, medications, blood pressure and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with ice packs, with your directions printed on the vial, sterile syringes and alcohol prep pads.
- Your physician stays reachable for questions and dose changes.
PT-141 + Oxytocin is supplied as a vial and syringe only. For PT-141 itself, step by step: how to get PT-141 prescribed online. Neighbouring comparisons are in kisspeptin vs oxytocin, kisspeptin vs PT-141 and peptides for libido.
References
What this is based on.
References
- Kingsberg SA, Clayton AH, Portman D et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials · Obstet Gynecol (2019) · PMID 31599840
- Behnia B, Heinrichs M, Bergmann W et al.. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples · Horm Behav (2014) · PMID 24503174
- Muin DA, Sheikh Rezaei S, Tremmel-Scheinost M et al.. Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study · Fertil Steril (2017) · PMID 28189292
- Veening JG, de Jong TR, Waldinger MD et al.. The role of oxytocin in male and female reproductive behavior · Eur J Pharmacol (2015) · PMID 25088178
- Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder · Obstetrics & Gynecology (2019) · PMID 31599847
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial · Women's Health (London) (2016) · PMID 27181790
- Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program · Journal of Women's Health (2022) · PMID 35147466
- Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women · CNS Spectrums (2022) · PMID 33455598
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction · International Journal of Impotence Research (2004) · PMID 14963471
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra · International Journal of Impotence Research (2004) · PMID 14999221
- Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response · Urology (2005) · PMID 15833522
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction · Annals of the New York Academy of Sciences (2003) · PMID 12851303
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
PT-141 + Oxytocin Dosage, answered.
At Pepti, 0.10 mL, which is 10 units on a U-100 insulin syringe, injected subcutaneously 2 to 4 hours before sexual activity, no more than 8 doses a month. Your physician sets your directions after reviewing your intake, and your exact dose is printed on the vial.
At 0.10 mL: 0.2 mg PT-141 and 0.1 mg oxytocin. The split is fixed by the formulation, so every draw delivers the same two amounts.
They are different products. The combination vial carries the same 2 mg/mL of PT-141 but is drawn at 0.10 mL, so each dose carries 0.2 mg PT-141 against 1 mg from a 50 unit PT-141 dose. The two labels have different directions and different monthly ceilings, and neither number applies to the other vial.
Pepti's directions say 2 to 4 hours before. That window follows the PT-141 component, which peaks in the blood about an hour after a dose. Your own label says which window applies to you.
No more than once in 24 hours, and no more than the monthly ceiling on your label, typically 8 doses a month. The ceiling exists because each dose raises blood pressure for a few hours and frequent dosing raises the risk of skin darkening.
Fifty. A 5 mL vial divided by 0.10 mL per dose is 50 doses, so at up to 8 a month the beyond-use date on the label, not the dose count, decides when it is replaced.
No. The approved bremelanotide label states that consecutive doses within 24 hours have not been shown to add anything and may add to the blood pressure effect. Message your care team rather than adjusting anything yourself.
No. The PT-141 trials used 1.75 mg by autoinjector, and the oxytocin studies used nasal sprays measured in IU. The combination vial has not itself been studied.
No. Pepti vials are multi-dose solutions shipped ready to use, with sterile syringes and alcohol prep pads. Nothing is reconstituted at home.
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.